Ribomic Inc
TSE:4591
Ribomic Inc
Other
Ribomic Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ribomic Inc
TSE:4591
|
Other
-¥7.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
Other
-¥48.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Other
¥2.8B
|
CAGR 3-Years
661%
|
CAGR 5-Years
22%
|
CAGR 10-Years
125%
|
|
|
PeptiDream Inc
TSE:4587
|
Other
-¥2k
|
CAGR 3-Years
98%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
Other
-¥1.6B
|
CAGR 3-Years
-1 058%
|
CAGR 5-Years
-278%
|
CAGR 10-Years
-87%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Other
¥32.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
26%
|
|
Ribomic Inc
Glance View
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 25 full-time employees. The company went IPO on 2014-09-25. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.
See Also
What is Ribomic Inc's Other?
Other
-7.1m
JPY
Based on the financial report for Dec 31, 2025, Ribomic Inc's Other amounts to -7.1m JPY.
